Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Long-Term Investments (2021 - 2025)

Historic Long-Term Investments for Roivant Sciences (ROIV) over the last 5 years, with Q4 2025 value amounting to $433.9 million.

  • Roivant Sciences' Long-Term Investments rose 4960.25% to $433.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $433.9 million, marking a year-over-year increase of 4960.25%. This contributed to the annual value of $302.9 million for FY2025, which is 2227.46% up from last year.
  • Per Roivant Sciences' latest filing, its Long-Term Investments stood at $433.9 million for Q4 2025, which was up 4960.25% from $412.3 million recorded in Q3 2025.
  • Roivant Sciences' 5-year Long-Term Investments high stood at $436.8 million for Q3 2021, and its period low was $180.4 million during Q2 2021.
  • Its 5-year average for Long-Term Investments is $299.4 million, with a median of $293.1 million in 2023.
  • Data for Roivant Sciences' Long-Term Investments shows a peak YoY increase of 7241.9% (in 2022) and a maximum YoY decrease of 4353.93% (in 2022) over the last 5 years.
  • Roivant Sciences' Long-Term Investments (Quarter) stood at $398.7 million in 2021, then tumbled by 31.67% to $272.5 million in 2022, then fell by 11.94% to $239.9 million in 2023, then increased by 20.89% to $290.0 million in 2024, then skyrocketed by 49.6% to $433.9 million in 2025.
  • Its Long-Term Investments stands at $433.9 million for Q4 2025, versus $412.3 million for Q3 2025 and $283.8 million for Q2 2025.